Business Wire

ITRS-GROUP

1.6.2022 10:02:12 CEST | Business Wire | Press release

Share
ITRS Group Launches Obcerv: Next Generation Technology Takes Performance Monitoring to the Next Level

ITRS Group, leading provider of real-time enterprise monitoring and analytics software to global financial institutions, today announces the launch of its newest product offering, Obcerv.

Amidst rapid digital transformation, modern IT operations have evolved from a traditional on-premises system to increasingly complex hybrid cloud environments. Traditional monitoring no longer addresses the complexities of the modern IT services stack and firms face a growing challenge to centralise data monitoring that can enhance performance, reveal patterns and trends in resource utilisation, and reduce outages.

The launch of Obcerv will introduce end-to-end visibility into infrastructure and applications, and through intelligent alert aggregation, it will identify the most likely source of a problem, enabling users to improve service delivery. Obcerv will act as both a data storage and analytics platform for critical monitoring, allowing users to gain full visibility and ultimately take back control of their systems.

Obcerv simplifies and accelerates traditionally complex monitoring systems with benefits including but not limited to:

  • The intelligent correlation of data from multiple data feeds and streams to simplify analysis
  • Data compression minimises storage costs, without having to aggregate the data as many tools do, ensuring data fidelity is maintained
  • Root cause analysis is accelerated, offering alerts based on commonality, thereby providing context and meaning to alerts
  • Unique APIs facilitate full interoperability, Obcerv can store data from other ITRS Group products, but from monitoring tools from other vendors too

Guy Warren, CEO of ITRS Group, said: “Monitoring is often seen as the canary in the coal mine: it may be able to tell you that something is wrong, but too often the message lacks context and meaning. Obcerv will provide IT operators with an understanding around why certain things happen, allowing them to accurately decide the best course of action.

In recent years, modern IT estates have become extremely complex, pushing many monitoring teams to the edge of their capability, leaving them struggling to deliver on uptime and reliability metrics. And with more than half of all firms experiencing at least a day of downtime each year, it is clear that monitoring solutions that are able to match the increasing complexities of the systems they are monitoring is required. Obcerv will not only help firms to gain full visibility across their estates but in doing so, it will enable them to regain control of them.”

For more information, visit www.itrsgroup.com/products/obcerv

About ITRS Group

ITRS Group ensures operational resilience for enterprises engaged in transforming their IT estate for a digital future, as well as the ongoing health of their on-premise, cloud-based or hybrid IT estate. By transforming the mass of raw data on performance, resource usage, and cost, ITRS Group’s solutions can detect and actively prevent problems and maximise cost efficiency, reassuring enterprises that their IT estates are running effectively. With experience in legacy technologies as well as the dynamic environment of cloud-delivery, agile development, and service-based architecture, ITRS Group’s people and software serve more than 4500 clients across industry markets. As new disruptors, new technologies, and new regulations continue to shape the marketplace and change the expectations of consumers, ITRS Group offers a best-in-class service and is a source of confidence for the always-on enterprise.

For more information, visit www.itrsgroup.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye